University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Biological Systems Engineering: Papers and
Publications

Biological Systems Engineering

2015

Bionanotechnology and the Future of Glioma
Peter A. Chiarelli
University of Washington, Seattle, pac47@uw.edu

Forrest M. Kievit
University of Washington, Seattle, fkievit2@unl.edu

Miqin Zhang
University of Washington, Seattle, mzhang@u.washington.edu

Richard G. Ellenbogen
University of Washington, Seattle, rge@uw.edu

Follow this and additional works at: https://digitalcommons.unl.edu/biosysengfacpub
Part of the Bioresource and Agricultural Engineering Commons, Environmental Engineering
Commons, and the Other Civil and Environmental Engineering Commons
Chiarelli, Peter A.; Kievit, Forrest M.; Zhang, Miqin; and Ellenbogen, Richard G., "Bionanotechnology and the Future of Glioma"
(2015). Biological Systems Engineering: Papers and Publications. 595.
https://digitalcommons.unl.edu/biosysengfacpub/595

This Article is brought to you for free and open access by the Biological Systems Engineering at DigitalCommons@University of Nebraska - Lincoln. It
has been accepted for inclusion in Biological Systems Engineering: Papers and Publications by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.

Surgical Neurology International
OPEN ACCESS

SNI: Neuro-Oncology, a supplement to Surgical Neurology International

For entire Editorial Board visit :
http://www.surgicalneurologyint.com

Editor:
Daniel Silbergeld, University
of Washington Medical Center,
Seattle, Washington, USA

Bionanotechnology and the Future of Glioma
Peter A. Chiarelli1, Forrest M. Kievit1, Miqin Zhang1,2, Richard G. Ellenbogen1*
Department of Neurological Surgery, 2Department of Materials Science and Engineering, University of Washington, Seattle, Washington 98195, USA

1

E‑mail: Peter A. Chiarelli ‑ pac47@uw.edu; Forrest M. Kievit ‑ fmkemt@uw.edu; Miqin Zhang ‑ mzhang@u.washington.edu;
*Richard G. Ellenbogen ‑ rge@uw.edu
*Corresponding author
Received: 13 October 14  Accepted: 15 October 14   Published: 13 February 15
This article may be cited as:
Chiarelli PA, Kievit FM, Zhang M, Ellenbogen RG. Bionanotechnology and the Future of Glioma. Surg Neurol Int 2015;6:S45-58.
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2015/6/2/45/151334
Copyright: © 2015 Chiarelli PA. This is an open‑access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract
Designer nanoscaled materials have the potential to revolutionize diagnosis and
treatment for glioma. This review summarizes current progress in nanoparticle‑based
therapies for glioma treatment including targeting, drug delivery, gene delivery, and
direct tumor ablation. Preclinical and current human clinical trials are discussed.
Although progress in the field has been significant over the past decade, many
successful strategies demonstrated in the laboratory have yet to be implemented
in human clinical trials. Looking forward, we provide examples of combined
treatment strategies, which harness the potential for nanoparticles to interact with
their biochemical environment, and simultaneously with externally applied photons
or magnetic fields. We present our notion of the “ideal” nanoparticle for glioma, a
concept that may soon be realized.
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INTRODUCTION
The ability to manipulate atoms, design supramolecular
structures, and generate useful function at the nanoscale
provides exciting opportunities for the treatment of
human disease. Bionanotechnology is specifically devoted
to materials possessing sub‑100 nm dimensions, and the
field possesses an interdisciplinary conceptual breadth
that can bring practitioners of quantum physics and
neurosurgery into the same discussion. The fabrication
of useful architectures, made up of multiple base parts
each with their own structural or functional role, is
the overarching principle in most modern biomedical
applications of nanotechnology.[22,89,158] Discrete molecular
forces – including chemical bonding, electrostatics, steric
interaction, and physical adsorption – are often harnessed
in tandem to generate a 3‑dimensional supramolecular
layer cake, with an overall function that benefits from
each of its chemical constituents.[92,100] Within this

nanoscaled assembly, specific materials are included
to provide desired properties such as eluding immune
recognition, crossing of biological barriers, providing
contrast in medical imaging, tumor targeting, releasing
a drug, or delivering gene therapy.[19] In the field of
neurosurgery, and specifically glioma therapeutics, there
is great interest, and much skepticism, in the rapidly
developing application of nanoscaled therapeutics.[18,181]
Many see nanotechnology as a means to attack glioma
at its source−the individual mutated genes, tumor stem
cells, or individual cellular metastases that represent
barriers to a cure. Materials designed with nanoscopic
dimensions are able to signal, home, and induce
damage in a coordinated fashion at the subcellular level,
permitting an unparalleled degree of control over the
targeted action of therapeutics.[135]
Glioma arises within the confines of a variably
intact blood–brain barrier (BBB),[101] is surrounded
S45
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by functional brain tissue that requires preservation,
spreads diffusely beyond the gross tumor margin,[55,101]
is prone to chemotherapy resistance by efflux and
direct drug inactivation,[147] and can be rapidly lethal.
The intersection of these obstacles in treatment makes
glioma a challenging pathological entity, and at the
same time a worthwhile target for investigation using a
tailored molecular‑scale approach.[12] Even with current
optimal treatment, including surgery, chemotherapy,
and radiation, high‑grade glioblastoma (GBM, WHO
grade IV) is associated with an average survival of
12–15 months.[98,160] Progression‑free survival is <24 weeks
after recurrence,[136,159] and the 5‑year survival is <5%.[49,127]
As a standard‑of‑care for GBM, radiation therapy is
known to extend survival approximately 2‑fold,[48,172] and
the drug temozolomide added to radiation increases
survival by an additional ~2.5 months.[125,159]
Given the modest treatment benefits of traditional
therapy, the investigation of nanostructured drug
formulations has intensified and has profited from
the significant experience in treatment of non‑glioma
neoplastic disease.[70,96] The first approval of an
antineoplastic nanotherapeutic by the US Food and Drug
Administration (FDA) occurred in 1994 for the treatment
of acute lymphocytic leukemia (ALL). The drug,
Oncaspar, was a poly (ethylene glycol) (PEG)‑coated
L‑asparaginase nanoparticle (NP) that demonstrated
increased plasma half‑life and decreased immunogenicity
compared to native L‑asparaginase.[130,142] To date,
oncaspar remains in clinical use for ALL. A liposomal
preparation of doxorubicin (Doxil) followed in 1995,
having been found similarly to increase circulation
half‑life, and was approved for treatment of Kaposi
sarcoma.[50,72] Liposomal formulations of vincristine,
daunorubicin, and cytarabine have been approved for
clinical use in systemic cancers,[69,144] with liposomal
cytarabine (DepoCyt) uniquely indicated for intrathecal
administration in lymphomatous meningitis, and
currently in phase 1 and 2 trials for central nervous
system (CNS) metastases from melanoma and breast
cancer.[27,28]
As illustrated by the examples of Oncaspar and
DepoCyt, biologically applied nanotechnology has
utilized the concepts of polymeric[23] and liposomal
NP systems. Drugs have been successfully loaded to
the particle surface, and also within the core of both
of these NPs.[94] Other biologically relevant nanoscaled
structures include solid lipid NPs,[122,134] metal−polymer
core‑shell NPs,[89] carbon nanotubes,[195] quantum dots,[71]
dendrimeric NPs,[7] and virus‑based nanocarriers.[150]
More complex structures with intriguing names such as
nanodiamonds[84,182] and nanoworms[2,83] have exploited
the influence of shape on function. In each of these
systems, anchoring materials are present and provide a
base structure, terminal surface groups allow conjugation
S46

of functional biomolecules, nontoxic polymers help to to
avoid immunogenicity, degradable materials can provide
pH‑ or enzyme‑dependent release, and porous materials
can help load or unload useful compounds.[129] The
promise of bionanotechnology lies in the vast ability for
modification; future technologies can be incorporated
into existing multi‑component constructs with relative
ease. In our opinion, the application of ultrasmall
customized therapeutics to glioma treatment will result
in many further advances applied both in the OR and in
the clinic. Our discussion here details current progress
in nanotherapeutics specifically for glioma, and explores
relevant advances in the field that may ultimately
transform the current notion of poor prognosis.

TUNABLE NANOMATERIALS FOR GLIOMA
IMAGING
The ideal nanoscaled imaging agent has the potential
to cross the BBB and interact with the tumor
microenvironment, providing detail about a specific
cellular population of interest. The enhanced permeability
and retention (EPR) phenomenon of NP accumulation
within tumors was first reported in the 1980s, and
nanomaterials were subsequently discovered to traverse
the intact BBB in 1995.[96,97] Harnessing the EPR effect
required an approximate size constraint of 30–100 nm.
Within this regime, NPs would extravasate from poorly
differentiated neoplastic vessels.[61,146] The slower
diffusion rate of the particle combined with the limited
intratumoral lymphatic drainage trapped the particle
within the tumor mass instead of allowing it to re‑enter
the systemic circulation.[110,115,178] The EPR accumulation
of NPs within glioma, as well as macrophage uptake of
NPs, both facilitate imaging contrast that can persist
beyond the time when NP has been eliminated from the
bloodstream.[167]
Nanoscaled materials can be modified to provide
visualization on conventional imaging modalities.
Contrast may derive from a magnetic resonance
(MR)‑ or computed tomography (CT)‑visible metal,[9]
MR‑active nonmetal (e.g., 19F, 13C),[57] PET‑active
radioisotope (e.g., 18F, 13N, 11C),[124,131] or chromophore/
fluorophore‑containing biomolecule.[158] Less well‑known
modalities also benefit from the use of nanomaterials, as
in photo‑acoustic imaging[174,188] where photon absorption
(e.g., near‑infrared (NIR) light absorption by gold
NPs[103] or carbon nanotubes[40]) produces microscopic
temperature fluctuations in the vicinity of the particle
and resulting acoustic waves are detected as ultrasound.
For magnetic resonance imaging (MRI), image contrast
is conveniently generated by the superparamagnetic
property of certain NPs including those made of iron
oxide.[157] Superparamagnetism denotes the presence of
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ultrasmall discrete magnetic domains, which fluctuate
continuously at rest, but become poled within an
external magnetic field and act as a coherent strong
moment.[89,121] While iron oxide NPs historically have
been used to generate intravoxel signal dephasing, and
thus darken the appearance of T2‑ and T2*‑weighted
images, more recent modifications have given iron
oxide NPs the ability to accelerate T1 relaxation, and
thus provide “bright” contrast on T1‑weighted scans.
Such modifications include doping the metal core
with gadolinium or manganese,[44,68] or manipulation of
nonmetallic coating size.[150] Figure 1 shows work from
our own group that highlights the appearance of iron
oxide NPs in vivo. Gadolinium‑enhanced imaging of an
orthotopic implanted GBM6 tumor at high magnetic
field [Figure 1a] is compared with a T2*‑weighted
image after PEG‑chitosan NP administration, NPs
highlight the cerebral microvasculature as well as
tumor [Figure 1b]. These NPs can accumulate in high
quantities within the tumor yielding contrast as shown
in a 3‑D reconstruction [Figure 1c]. A photograph of the
implanted tumor is provided for comparison [Figure 1d].
Nanomaterials have tunable size, hydrophobicity, and
surface charge [Table 1]. These properties can be
adjusted to facilitate tumor homing and to avoid rapid
elimination. NPs with sizes between 15 and 100 nm
are ideal for ensuring long‑circulation times in blood.
Below a hydrodynamic size of 10–20 nm, particles will
be rapidly filtered by the kidneys, and at sizes greater
than ~150 nm, particles will be sequestered by the
reticuloendothelial system (RES), with uptake into the
spleen.[75,178] Although particle uptake by the liver will
inevitably occur even within this ideal size range, half‑life
in circulation can remain long (2–40 h).[126] To optimize
plasma half‑life, Geng et al. constructed tube‑like
PEG‑poly (caprolactone) micelles with small diameters
in cylindrical cross‑section (~20 nm), and very large
cylindrical length (~18 µm).[54] The group found these
structures would persist in the bloodstream for >5 days

since they were able to fit lengthwise through tight
microvascular spaces and were sufficiently long to
mechanically hinder uptake into macrophages.[54]
Hydrophobic drugs and surfaces are known to be targets
for opsonization, and modifying a nanomaterial surface to
be more hydrophilic (e.g., coating with PEG, chitosan, or
albumin)[108,171] can increase circulation time. Amphiphilic
molecules such as poloxamer 188 or polysorbate 80 have
been used to provide the same circulation benefits by
presenting a hydrophilic surface, while retaining internal
hydrophobic regions that facilitate entry through the
brain endothelium.[162,173] Surface charge can be altered
by incorporating small molecules or polyelectrolytes.
Positively charged surfaces promote BBB penetration by
inducing physical adsorption to the endothelium.[107,116]
In culture, cationic NPs are readily taken up into the
cells at the periphery of tumor spheres, while anionic
NPs demonstrate lower intracellular uptake.[90] Curiously,

a

c
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d

Figure 1: In vivo administration of iron oxide nanoparticles.
(a) Gd-enhancedT1-weighted image and (b) iron oxide NP-enhanced
T2*-weighted image of mouse glioblastoma tumor (GBM6). (c) 3D
reconstruction of a T2-weighted image with inverted contrast after
NP injection. (d) Coronal cross-section photograph of the brain for
comparison, near the posterior extent of the tumor

Table 1: Fundamental nanomaterial characteristics and their observed impact on tumor localization
Size (nm)

Hydrophobicity

Surface charge

Small

Large

<10

<20

<70

<100

>150

Rapid glomerular
filtration

More easily exits tumor cells
once internalized (↓ EPR)

Improved convective flow
through tumor and normal
brain

Permits
tumor entry
via EPR effect

Difficult cell entry
via endocytosis
Clearance by RES

Hydrophilic

Amphiphilic

Hydrophobic

Increased circulation
half‑life

Increased BBB penetration

Cleared rapidly by
reticulo‑endothelial system

Cationic

Uncharged

Anionic

Adsorptive‑mediated
BBB transcytosis;
Cell membrane
disruption at high charge

Reduced charge may facilitate
spread through tumor ECM

Reduced brain tumor
cellular uptake in vivo;
Improved diffusion within
interstitium
S47
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anionic particles show improved distribution throughout
the space external to the cells. Zhou and colleagues
formulated a poly (L‑lysine) NP coated with acid‑labile
β‑carboxylic amide groups, whose charge switches in the
presence of acidic tumor microenvironment to exploit
the apparent diffusive benefits of negative charge with
the permeability benefits of positive charge.[149,184,198]
The potential to maintain a high plasma concentration
and interact favorably with the blood−tumor interface
make NPs highly useful for glioma imaging. Particles
that can generate contrast on two,[171] or even three[92]
unique imaging modalities have been constructed,
with preferential accumulation seen within the
tumor mass over normal brain. A current human
clinical trial is in progress, testing the application
of a magnetite NP coated with polyglucose sorbitol
carboxymethylether (ferumoxytol) compared with
standard gadolinium contrast for assessment of BBB
permeability changes after combination chemotherapy
in glioma.[29] The study seeks to use the NP as a means
of calculating tumor blood volume,[26] and to show a
benefit of the NP in distinguishing pseudo progression
from tumor recurrence. There has yet to be a human
clinical trial for imaging using a biochemically targeted
NP, although such a trial will certainly have value given
the high affinity of targeted particles for glioma and the
relatively low toxicity of such materials.[171] Biochemically
targeted materials will likely be necessary to provide
uptake in areas with minimal EPR effect as vascular
permeability may be regionally heterogeneous within
the glioma mass.[47] In the following section, we discuss
the role of molecular targeting as it pertains to NP drug
delivery.

DRUG DELIVERY AND GLIOMA TARGETING
The use of targeted nanomaterials for drug delivery
has intensified over the past decade.[128] Recent work in
animal glioma models has used targeted NPs to delay
tumor growth and improve survival.[62,63,183] A majority of
research, to date, has utilized orthotopic tumor models
in mice and rats, including implanted human (e.g., U87,
T98G, GBM6) and mouse (e.g., C6) cell lines. Transgenic
murine models of glioma have also been used,[66] and
although these may not recapitulate human tumor biology
in the same manner as implanted human cells, they are
thought to better mimic the tumor microenvironment,
tumor cell–stroma interactions, and invasive behavior.[43]
Intracranial murine tumors commonly grow to lethal size
by ~2 months, and intervention via NP therapeutics is
usually performed ~1 month after implantation, once
the tumor has reached intermediate size.[9] Reviewing
the body of literature, it is common to see successful
studies in rats and mice with a reported median
survival increase of ~20 days,[21] with some studies
S48

demonstrating long‑term remission in a percentage
of the treated cohort.[155] Given the large number of
successful animal studies over the past decade, and the
low reported toxicity of these synthesized materials,[88]
we expect to see clinical trials soon appear for targeted
particle systems in glioma. Rigorous testing of short‑ and
long‑term particle safety will need to be accomplished,[67]
and more detailed study of particle bio distribution will
be necessary in large animal models.[117,152] Although a
great number of laboratories are adept at small‑batch
NP synthesis, scaling up the synthetic volume and
maintaining target molecule attachment under
conditions of clinical‑grade sterility require time and
funding.[21]
Our optimism with regard to the arrival of clinical trials
for glioma‑targeted nanotherapeutics is galvanized by
a number of existing trials for non‑CNS pathology.
For instance, drug‑carrying liposomes targeted to the
transferrin receptor are in phase II clinical trials for gastric
and esophageal adenocarcinoma,[34] and PEGylated
poly(lactic-co-glycolic acid) (PLGA) NPs targeted to
glutamate carboxypeptidase II are in phase 2 trials for
multiple solid tumors, including prostate cancer.[30] Toward
the treatment of recurrent glioblastoma, trials for an
intravenous nontargeted nanoliposomal formulation of
the topoisomerase 1 inhibitor irinotecan (CPT‑11) have
been initiated, with a phase 1 trial currently underway
for single‑agent therapy.[31] This same agent has shown
promise when injected intracranially, and a phase 1 trial is
enrolling patients for convection‑enhanced delivery (CED)
of CPT‑11 at escalating doses from 20 to 80 mg.[33]
To achieve maximal tumor uptake in vivo, a NP can
be conjugated to a homing agent that seeks a target
expressed both on tumor cells and on tumor‑associated
vascular endothelium. Table 2 presents an alphabetized
list of the most common homing targets found to
increase NP uptake in glioma. The table also includes
a list of popular polymeric coatings, NP configurations,
and (nongenetic) therapeutic agents used in current
research.
The targets shown in Table 2 include a number of
receptors overexpressed on rapidly dividing cells. For
instance, the transferrin receptor is normally expressed
on brain endothelial cells, as well as hepatocyte,
erythroid, and placental cells.[166] In the setting of a brain
neoplasm, vascular expression of transferrin receptor
is upregulated.[163] Zhang et al. delivered PEGylated
immunoliposomes past the BBB to mice bearing U87
glioma xenografts via targeting antibodies that bound
transferrin and insulin receptors.[194] Further research
with insulin receptor targeting alone also resulted in
increased NP accumulation.[164] Expression of the folic
acid receptor at the BBB has been found to facilitate
brain entry of drug‑loaded targeted NPs,[79] and
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Table 2: Example homing targets, polymeric coatings,
nanoparticle configurations, and therapeutic agents
utilized in nanoparticle drug delivery for glioma
Nanoparticle homing targets in Glioma
Diptheria toxin receptor
(via CRM197)
EGFR Fibrin (via CREKA peptide)
Folate receptor
IL‑13 receptor
Insulin receptor
Laminin
LDL receptor
LRP (LDL receptor‑related protein)
Polymers

Mitochondria
(via CGKRK peptide)
MMP‑2/annexin A2 (via chlorotoxin)
Nucleolin
Target of RVG29
Target of HIV TaT peptide
Transferrin receptor
Vascular integrin αVβ3
(via RGD peptide)

Alginate
Chitosan
CSA (cationic serum albumin)
Gelatin
PAMAM Poly (amidoamine)
PBAE Poly (β‑amino ester)
Nanoparticle Configurations

PBCA poly (butylcyanoacrylate)
PCL poly (ε‑ caprolactone)
PEG poly (ethylene glycol)
PLA poly (lactic acid)
PLGA poly (lactide‑co‑glycolide)
PS polystyrene
Therapeutic Agents

Dendrimeric
DNA/RNA‑based
Lipid‑based
Metallic core‑shell
Micellar
Polymer aggregate
Viral‑based

Doxorubicin/Epirubicin
Etoposide
Irinotecan
Methotrexate
Paclitaxel
Temozolomide
Pro‑apoptotic peptides

targeting of epidermal growth factor receptor (EGFR)
overexpression on intracranial U87 tumors has similarly
facilitated antineoplastic activity, with encapsulated
chemotherapeutics delivered both intravenously[114]
and via CED.[63] A related EGF peptide known as
heparin‑binding EGF‑like growth factor (HB‑EGF) has
been discovered on the endothelial surface, and is known
to bind diphtheria toxin.[51] The use of mutated nontoxic
formulations of diphtheria toxin has correspondingly been
shown to facilitate BBB crossing.[52] Conjugation of IL‑13
to liposomes has increased drug transport to intracranial
U251 implants as glioma cells overexpress the IL‑13
receptor α2.[109] More esoteric receptor‑targeting strategies
have also shown promising results in glioma, such as
the conjugation of rabies virus glycoprotein 29 (RVG29)
peptides to dendrimeric NPs.[106] The increased brain
uptake was attributed to binding of RVG29 to GABAB
or nicotinic acetylcholine receptors.[106] A final popular
target is the overexpressed low density lipoprotein (LDL)
receptor, although LDL receptor‑related proteins (LRP)
also function well for targeting. While NP coating
with agents including apoE or polysorbate 80 have
induced binding to the LDL receptor,[95] attachment of
β‑amyloid precursor protein has resulted in binding to
LRP.[93] LRP has been found both on glioma cells and
BBB endothelium, with specific intracranial targeting and
drug delivery having been demonstrated in a mouse U87
model.[41,183]

Similar to the case of LRP, other nonantibody proteins
are overexpressed by glioma and appear in detectable
quantities on the endothelium of tumor vessels.
Examples include laminin 411,[42] nucleolin,[46] and
fibrin.[25] The penta‑peptide CREKA (cysteine−
arginine−glutamic acid−lysine−alanine) was chosen
with specific binding affinity for fibrin, and was found to
yield particle deposition within GBM tumors 1 h after IV
injection.[25] Other successful examples of short peptide
binding include the tri‑peptide RGD (arginine−glycine−
aspartic acid) that binds to αVβ3 integrin on immature
endothelial cells,[10,20] and the penta‑peptide CGKRK
(cysteine−glycine−lysine−arginine−lysine) that binds to
heparan sulfate on tumor endothelium.[2]
The 36‑amino acid peptide chlorotoxin (CTX) has
been the subject of much focused research.[88,89,168,169]
CTX is derived from the venom of the scorpion Leiurus
quinquestriatus, and can facilitate NP entry across
the BBB into tumor cells via binding of overexpressed
matrix metalloproteinase‑2 and annexin A2.[86] Figure 2
demonstrates accumulation of fluorescently labeled
CTX‑conjugated iron oxide NPs within a GFP expressing
C6 glioma xenograft, by ex vivo fluorescence imaging,
histology/iron staining, and detection of fluorescent label
within individual cells.
While NPs are typically thought of as passive smart
delivery vehicles, they can also be engineered to actively
move throughout the tumor. Recent work has opened up
the possibility to engineer NPs that migrate throughout
the tumor with targeting agents that “walk” along antigen
receptors.[132] Cells can also be used as delivery vehicles
for NPs to provide active migration to and throughout the
tumor. Microglia have been used for such a purpose as
they are chemo attracted to brain tumors.[138,139] Neuronal
stem cells (NSCs) have been used as delivery vehicles
for glioma; NSCs have high specificity to brain tumor
tissue and are able to actively move throughout the
tumor.[1] The majority of this work has been performed
using NSCs engineered to express oncolytic viruses
or tumor suppressor proteins.[140] Importantly, NSCs
can be loaded with NPs without affecting their normal
cellular function and can be tracked using MRI.[14] We
foresee NSCs being used as a Trojan horse to deliver
multifunctional NPs to gliomas. The ability to track
NSCs, as well as engineered T cells[13] and dendritic cells[6]
for immunotherapy[137] when loaded with NPs will provide
a more useful platform for optimizing these therapies.
Imaging data could reveal if a therapeutic response is
correlated with successful accumulation of cells in the
tumor and with appropriate tumor eradication.

NANOPARTICLE GENE THERAPY
Nanotechnology provides tools to overcome current
limitations in nonviral glioma gene delivery, and we
S49
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Figure 2: Targeting of iron oxide nanoparticles to orthotopic C6 glioma xenograft tumors in mice. (a) IVIS bioluminescent imaging of
luciferase signal demonstrates tumor location. (b) Fluorescence imaging of red channel (710 nm) shows concentrated presence of cy5.5
fluorophore-labeled NPs within the glioma mass. (c) Hemotoxylin and eosin, and (d) prussian blue/nuclear fast red stained sections of
the tumor show accumulation of iron oxide 24 h after injection. (e) Fluorescence microscopy of C6 cells loaded with CTX/cy5.5-bound
NPs in vitro

believe that nanomaterial‑facilitated gene therapy
will eventually be incorporated into routine glioma
management. Avenues of gene therapy for glioma
include: (i) replacement of damaged genes with
functional counterparts, (ii) knockdown of proteins
required for glioma cell survival using small interfering
RNAs (siRNAs) or short hairpin RNAs (shRNAs),
(iii) delivery of genes that code for enzymes that
convert inert prodrugs into cytotoxic compounds,
and (iv) modulation of the stromal compartment by
inhibiting angiogenesis or activation of the immune
system. Gene therapy offers significant advantages
over small‑molecule drugs, as many targets are
currently “undruggable” with existing therapeutics.[176]
Furthermore, genetic therapies may facilitate key cellular
transformations such as terminal differentiation of brain
tumor stem cells.[162] The translation of gene therapies
into the clinic has been hindered by the lack of a safe
and effective gene delivery vehicle. Most clinical trials
utilize viral vectors as they are effective at transferring
genetic material into target cells. However, systemically
administered viral gene transfection is limited by a
rapid clearance rate due to recognition by the immune
system and lack of tumor penetration caused by their
large size (~100 nm).[99]
NPs have been proven capable of binding and protecting
a nucleic acid payload. This was achieved initially by
encapsulating nucleic acids into liposomes. The surface
of the liposome can be modified with targeting and
imaging agents with the nucleic acid protected in the
liposome core. An early‑adopted DNA gene therapy
utilized liposomes to deliver a suicide gene, herpes
simplex virus thymidine kinase, along with ganciclovir
S50

as the prodrug.[37] Cationic liposomes were also used to
deliver the gene encoding interferon‑β (IFN‑β). Results in
mice prompted a limited human trial using intratumoral
injection of this formulation in five patients, with two
glioma tumors demonstrating growth arrest for 10 weeks,
and two others showing size reduction that persisted
for ~16 months.[187] However, to date, this drug has not
progressed past stage 1 clinical trials.
In addition to lipid particles, cationic polymer or
core‑shell NPs may also bind negatively charged
nucleic acids through electrostatic interaction, and the
condensation of these nucleic acids into the polymer layer
may provide them with a means of protection. Nucleic
acid protection can be challenging in complex fluids
such as blood, where particle aggregation or nonspecific
binding of serum proteins and cells can occur. To further
protect nucleic acids, NPs can be stabilized through
coating with PEG[133,193] or zwitterionic polymers[185] that
create a hydration layer surrounding the NP. A particle
designed in this fashion delivered tumor necrosis
factor related apoptosis inducing ligand (TRAIL) by
encapsulation within PEG/PLA NPs. TRAIL induces cell
death in glioma cells that have the appropriate receptors
overexpressed on their surface.[189]
More recently, significant focus has been placed
on siRNA delivery to knockdown expression of
genes required for glioma cell survival.[170] Cationic
liposome‑mediated delivery of c‑Met siRNA decreased
c‑Met expression in orthotopic glioblastoma tumors in
mice, and suppressed tumor growth.[76] Effective delivery
of siRNA against EGFR was also demonstrated, both
with intravenous liposomal delivery to a subcutaneous
implanted U251 glioma model,[81] and by attachment
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to crosslinked dendrimeric iron oxide NPs followed by
intracranial delivery to a transgenic glioma model.[3]
Modified siRNAs have also been constructed that are
protected from nuclease degradation and are readily
taken up into cells.[24,85,177,180] These modified siRNAs
provide the opportunity to focus NP engineering
strategies away from siRNA protection and toward
prolonging circulation time, increasing site‑specific
delivery, and promoting distribution throughout the
tumor. By reducing the design constrains on NPs, we
may thus simplify their construction and accelerate
clinical translation.
On the horizon are exciting gene therapies whose
application to glioma may be facilitated by nanoscaled
delivery agents. For instance, spherical nucleic acid NP
conjugates have been constructed from gold NPs coated
in a densely packed, highly oriented layer of siRNA.
These structures have been found to be well protected
from nuclease degradation and provide highly efficient
knockdown.[74,141] Clustered regularly interspaced short
palindromic repeats (CRISPR)/Cas9 technology has
quickly become a mainstream tool to regulate gene
expression.[35,113,143] A Cas9 nuclease attached to an
RNA guide makes a double‑strand break at the RNA
target sequence in the genome. Modified Cas9 can also
induce DNA base methylation, chromatin modification,
and even activation of gene expression. RNA
activation (RNAa) also allows control of gene expression,
and to date it has been less widely adopted.[73,82,102]
Using RNAa, double‑stranded ribonucleotide segments
are delivered, which interact with the promoter region
of a gene to induce expression, providing a means to
reactivate tumor suppressor genes without the need to
deliver the entire coding sequence.
Human clinical trials have shown some success with NP
siRNA delivery, indicating the approach may soon be a
viable option for glioma.[38] We are currently at a point
where the library of known glioma targeting agents is
progressively being applied to the transport of genetic
material in small animal models. The targeting agents
can facilitate trafficking not only to the glioma cell
itself, but also to the nucleus or perinuclear region. NPs
targeted with the peptide chlorotoxin, for instance, were
found to promote localization in the perinuclear region
with resulting high transfection efficiencies.[87,88] Genetic
therapy in glioma is likely to yield optimum benefit as
part of a combined treatment strategy. The use of gene
therapy via NPs, in combination with chemotherapy drugs
attached to the particle, could provide maximal benefit
due to the co‑localization of therapy. As we will discuss
next, the third arm of a combined future treatment
strategy can be tumor ablation using ingeniously applied
chemistry and biophysics, to promote energy deposition
at the site of the NP.

NANOMATERIAL
TISSUE
ABLATION−
CREATIVE
APPROACHES
TO
NANONEUROSURGERY
Successful NP drug or gene delivery must adhere to
a delicate chemical and biological scheme including:
(i) strong attachment of the therapeutic payload in high
quantities, (ii) guarding of the beneficial agent from
detachment in the bloodstream, (iii) carrying of the drug
or gene into the tumor, and (iv) release of the payload
once inside the cell. The chemistry of NP design often
involves a limited number of competing reactive sites to
attach drug and targeting agent, making the addition of
both at appropriate quantity a challenge. In contrast, it is
conceptually less complex to design a NP, which simply
delivers itself to a glioma mass. Once internalized, NPs
can be “activated” from outside the body in a number
of ways−including photons and magnetic fields−causing
them to release energy and ablate tissue with a level of
precision that is determined by their targeting efficiency.
The particles are otherwise biocompatible and nontoxic
to cells, until the external trigger is initiated. If delivered
appropriately, particles can accomplish selective tumor
destruction, with no entry tract and minimal off‑target
tissue damage. Such a nanosurgical approach could prove
of great value especially for the treatment of deeply
situated glioma, in which location makes conventional
surgery counterproductive.
The interaction between externally applied photons and
an internalized material was the conceptual basis of
photodynamic therapy (PDT) − a principle first described
over 100 years ago.[120] Embedded photosensitizers were
found to generate singlet oxygen (1O2) when excited
with the appropriate wavelength, and would result in free
radical damage at a distance of ~100 nm.[119] The visible
light‑activated (630 nm) compounds porfimer sodium
and 5‑aminolevulinic acid are well known examples of
photodynamic agents. Porfimir sodium is in clinical use
for nonsmall cell lung cancer and esophageal cancer,[80]
and is also in clinical trials for glioma.[32] PDT has been
under investigation for neurosurgical purposes for over
two decades, and photoactivators have many novel
applications through their incorporation into nanoscaled
materials.[8] Santos et al. recently injected single‑walled
carbon nanotubes into murine temozolomide‑resistant
glioma flank tumors. These nanotubes absorb NIR light
from an external laser source without the need for an
additional photoactivator, resulting in radiative relaxation
and hyperthermic tumor ablation.[145] A similar concept
has been demonstrated for intracranial tumors using an
external NIR source that interacts with hybrid silica‑gold
nanoshells.[39] Direct neurosurgical investigation of
this technology is currently expanding, with lasers
positioned either adjacent to an open resection cavity,
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or intracranially using long needles similar to those for
laser‑induced interstitial thermotherapy (LITT).[161,190]
Particles can either be injected intravenously or directly
into the brain using the principles of CED.[5,11]
NPs can also interact with photons outside the UV‑visible
infrared region of the electromagnetic spectrum, and can
increase the tissue‑ablating potential of very low frequencies.
In the radiofrequency (RF) regime, shortwave (13.56 MHz)
RF fields emitted at low power will induce negligible
damage to tissues on their own.[53] When these RF waves
encounter an electron‑dense nanomaterial (e.g., metallic
NP, carbon nanotube, quantum dot), the vibrational
energy release from RF‑induced electron movement can
result in amplified resistive heating, which occurs on
a length scale of ~100 µm around the particle.[58] The
NPs effectively focus the energy from the broadly applied
RF field onto specific sites of interest. Heating at these
microscale dimensions can occur at a rate of 1–3°C/s, with
local boiling temperatures attainable within minutes.[58,59]
This is in contrast to standard RF ablation, which involves
higher delivered power, and damages bulk tissue within
a radius of 2–4 cm from a probe tip.While standard RF
abliation has been involved in human clinical trials for
glioma,[45,179] and although applications of targetted NP−
RF ablation have been successfully demonstrated in animal
models of nonglioma neoplasms,[16,60] further investigation
using targetted RF nanotherapeutics for glioma is currently
warranted.
Within the high‑frequency spectral range, X‑ and
gamma‑rays are known to interact with metalic NPs,
especially those composed of metals having a high
atomic number.[36] When high‑energy photons encounter
an appropriate electron‑dense heavy metal, they yield a
localized deposition of energy due to inner‑shell electron
transitions in the metal atom, followed by relaxation
and local emission of photons and electrons from the
metal itself (Auger effect).[36,123] This electron cascade
then triggers free radical formation in the surrounding
solution, which can damage DNA, cell membranes, or
cellular machinery. As perceived by the involved tumor
cells receiving radiation damage, this spatially localized
deposition of X‑ or gamma‑rays energy acts similar
to the high linear energy transfer (LET) behavior of
particle radiation.[17] Although this effect also occurs with
individual metal atoms, the NP delivery scheme provides a
biocompatible polymer coating and prevents toxicity of the
metal.[192] Success has been achieved with this approach
using NPs composed of silver[105] and gadolinium,[36]
although the most widely adopted material in this respect
has been gold.[4,15,64] Hainfeld et al. demonstrated good
response of intracranial Tu‑2449 × enograft gliomas to 30
and 35 Gy doses of 100 kVp X‑rays, administered in the
presence of nontargeted gold NPs.[65] In this study, 5 of 9
mice remained alive one year after treatment, compared
with 2 of 11 mice in the radiation‑only group. Combined
S52

technologies have also been described, such as the
self‑lighting PDT technique.[19] In this method, ionizing
radiation is applied externally to activate photon release
from a scintillation‑luminescent NP. Visible light produced
by the particle then activates adjacent PDT‑active
photosensitizers, accomplishing the 1O2‑dependent action
of PDT, and circumventing the problem of visible light
penetration through biological tissue.
Despite the body of research using photons to activate
biologically internalized NPs, perhaps the greatest
progress in external manipulation of NPs has been
with magnetic fields.[151] Magnetic materials, including
NPs of appropriate composition, undergo magnetic
moment hysteresis and enhanced Brownian motion
when subjected to a rapidly alternating field.[77,151,175]
These effects contribute to thermal energy release
and result in localized heating. The principles of
magnetic hyperthermia have been under investigation
for over 60 years,[56] and the first applications of this
technology for treatment of glioma were initiated
in the late 1980s by Stea et al., using ferromagnetic
seeds.[153,154] A wide range of preclinical studies in
animals have demonstrated significant survival benefit
in glioma when using superparamagnetic iron oxide
NPs followed by magnetic hyperthermia.[78,104,186] This
success prompted human clinical trials based in
Germany using an aminosilane‑coated iron oxide NP,
with magnetic thermotherapy added to conventional
treatment. The first results were published in 2007,[77,111]
and the most recent were published in 2011.[112,165]
The combined therapy yielded an average survival
of 13.4 months after glioma recurrence, in a cohort
of 59 patients. Comparison against a conventional
treatment cohort with comparable tumor size and
demographics showed a survival of 6.2 months
after recurrence. The study selected patients with
supratentorial GBM, up to 3 foci, a maximum tumor
size of 7 cm, and a Karnofsky score >60 at the time
of enrollment. NPs were delivered to the tumor through
direct intracranial injection (concentration 112 mg/ml)
of ~4.5 ml of solution, and were exposed to a magnetic
field alternating at 100 kHz. Transient intratumoral
temperatures of approximately 51°C were reached.
Figure 3 displays representative CT‑based maps of NP
after instillation for this therapy. After postmortem
study of relevant brain tissue, the authors concluded
that magnetic heating contributed to additional
coagulative necrosis in the areas containing the NP.[165]

TOWARD A CURE−NANOTECHNOLOGY IN
THE OPERATING ROOM AND IN THE CLINIC
The methods of NP tissue ablation and of NP drug−
gene delivery, when viewed together, provide a glimpse
of the great potential that nanotechnology has in
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the field of glioma. To date, the literature on these
approaches has remained discrete, and the presence of an
integrated literature exploring the potential of combined
targeting, molecular therapeutics, and photon/magnetic
ablation remain in the formative stages. Rather than
simply allowing treatment through a single modality,
nanotechnology can act as a platform for multi‑modal
glioma treatment, employing many useful approaches
simultaneously. We envision a treatment scheme that
incorporates a number of therapeutic strategies via a
common nanoscaled agent for targeted delivery.
Over the past decade, there has been much speculation
with regard to the “theranostic” potential of NP
materials. Utilizing a single vehicle to assist in both
diagnosis and treatment brings the worlds of clinic and
the operating room closer together. It also brings exciting
principles of physics and spectroscopy closer to the
direct management of glioma. From a purely conjectural
standpoint, we reflect on a hypothetical particle that is
injected intraoperatively after resection, with magnets
closely positioned around the resection cavity to draw
iron oxide NP quickly to the margins of the tumor
bed.[191,196] Such a NP would carry one or more molecular
targeting agents to promote internalization past the BBB
and to the tumor cell nucleus. After surgery, based on the
estimated degree of successful NP delivery−as gauged by
the superparamagnetic signature on MRI−radiation dose
for NP‑enhanced ionizing‑beam therapy could be chosen.
Such therapy would act synergistically with the otherwise
prohibitively hydrophobic chemotherapeutic drug that
was simultaneously bound to the particle.
A second, and separate, hypothetical scenario involves
the treatment of gliomas that are poor candidates for

resection due to deep intracerebral location. In this
setting of highly sensitive surrounding anatomy, CED
of the NP formulation (potentially performed at the
same time as stereotactic biopsy) would be followed by
imaging to confirm the absence of off‑target particle
diffusion (e.g., to the brainstem or near large cerebral
vasculature). Subsequently, magnetic convective heating
would be applied, and would act along with the combined
action of oral chemotherapy and NP‑bound gene therapy.
Such hypothetical combined therapeutic strategies may
soon present viable options for clinical testing.[197] One
concept explored by Karabeber et al. used NPs coated with
a Raman‑active 4,4′‑bipyridine dye loaded in between a
gold core and a silica outer shell.[83,92] The group performed
a sequential resection of tumor in an infiltrative glioma
model, while applying a handheld surface‑enhanced
Raman scattering (SERS) probe to determine if neoplastic
cells remained at the margins [Figure 4]. The study
found that resection of all Raman‑active microscopic
tumor foci resulted in the absence of local tumor cells
on follow‑up immunohistochemistry. The NPs, in this
example provided intraoperative feedback with cellular
precision. Another example from Veiseh et al. described
a dual MR‑ and NIR‑active NP, targeted with chlorotoxin
to pass the BBB.[171] This same particle has been recently
conjugated with O6‑benzylguanine and injected directly
into GBM6 gliomas, with excellent visualization on MRI,
minimal off‑target toxicity, and demonstration of survival
benefit.[156]
A schematic of our idealized future nanotherapeutic
incorporating a number of the features described above
is displayed in Figure 5. The field of nanotechnology
a

d

Figure 3: Human intratumoral injection of iron oxide NP, for clinical
study of magnetic hyperthermia. (a) Coronal CT image displays
hyperdense NP mass, with surrounding isothermic lines of simulated
treatment temperatures (red=50°C, blue=40°C). (b) Fused CT–MRI
images showing enhancing glioma margin (brown), with respect
to the iron oxide infusion (purple). Adapted with permission from
Maier-Hauff et al.[112]

c

b

e

Figure 4: Intraoperative spectroscopy. A handheld SERS probe
assisted in optimizing surgical resection of infiltrative glioma
from the brain of a mouse, after Raman-active nanoparticles were
delivered intravenously. Tumor site before (a and b) and after
(c) resection are displayed, as well as a schematic of the handheld
probe in use (d), and an example spectrum of the particle detected
in cells at the tumor margin (e). Adapted with permission from
Karabeber et al.[83]
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12.
13.

14.

15.

Figure 5: Conceptualized ideal nanoparticle. A metal core is used
for image contrast and radiation/magnetic therapy, while the
polymeric shell provides biocompatibility and functional sites for
attachment of homing molecules, nucleic acids, chemotherapeutics,
and optically active moieties

provides an array of options for the improved diagnosis
and treatment of glioma. The principles of smart
molecular design allow us to choose simultaneous
treatment strategies that work synergistically to eradicate
tumor cells both within the enhancing margin and
beyond. The existing body of work and current clinical
trials suggest that such combined therapeutic strategies
will likely be ready for clinical testing within the next
5–10 years. Rather than a substitute for surgical therapy,
nanoscaled treatment modalities provide an adjunct
to modern surgical strategies−improving the extent of
resection, working noninvasively to eradicate tumor cells
remaining after surgery, and targeting the biomolecular
mechanisms that make glioma a challenging neoplasm.
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